Previous studies have demonstrated the potential of utilizing bispecific radioligands to increase the detection sensitivity of prostate cancer imaging, such as bispecific PSMA/gastrin-releasing peptide receptor (PSMA/GRPR) radioligands that have higher tumor uptake in PSMA- and GRPR-expressing mouse tumor models compared to monospecific radiotracers [24]. This evidence concerns the gene FOLH1 and prostate cancer.